DU-176b tablets + Warfarin potassium tablets

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atrial Fibrillation

Conditions

Atrial Fibrillation

Trial Timeline

Mar 1, 2007 → Sep 1, 2008

About DU-176b tablets + Warfarin potassium tablets

DU-176b tablets + Warfarin potassium tablets is a phase 2 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00829933. Target conditions include Atrial Fibrillation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00829933Phase 2Completed

Competing Products

20 competing products in Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonistDaiichi SankyoPhase 3
77
OAC aloneDaiichi SankyoApproved
85
Edoxaban + ASADaiichi SankyoPhase 3
77
DU-176b tablets + DU-176b tablets + Warfarin tabletsDaiichi SankyoPhase 2
52
Edoxaban + Apixaban + RivaroxabanDaiichi SankyoPre-clinical
23
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based RegimenDaiichi SankyoPhase 3
77
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarinDaiichi SankyoPhase 2
52
EdoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoApproved
85
Edoxaban + Warfarin + EnoxaparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3
77
dabigatran, rivaroxaban, apixaban or edoxabanDaiichi SankyoPre-clinical
23
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban-based Regimen + VKA-based RegimenDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
85
EdoxabanDaiichi SankyoPre-clinical
23